Investing
Pfizer, BioNtech say flu-COVID shot generates immune response
© Reuters. A compagny logo is seen at a Pfizer office in Puurs, Belgium, December 2, 2022. REUTERS/Johanna Geron/File Photo
(Reuters) – Pfizer (NYSE:) and German partner BioNTech (NASDAQ:) said on Thursday that their vaccine to prevent flu and COVID-19 generated a strong immune response against the virus strains in early- to mid-stage trials.
The companies said they plan to start a late-stage trial in the coming months.
Read the full article here
-
Make Money6 days ago
10 Ways to Make Money As a Graphic Designer
-
Personal Finance5 days ago
If you are 60 years old, new 401(k) rules could save you money
-
Investing6 days ago
Could Easier Cancellations Build Customer Loyalty?
-
Investing4 days ago
Bank regulator gives BlackRock new deadline on bank stakes, Bloomberg reports By Reuters
-
Side Hustles6 days ago
Trump’s 2025 Inaugural Committee Raises Record $170 Million
-
Investing5 days ago
It’s Time to Rewrite Your Company’s Values — Here’s How
-
Side Hustles5 days ago
5 AI Books Top Entrepreneurs Are Reading in a Rush for 2025
-
Side Hustles3 days ago
LA Rental Prices Skyrocketing Despite Price Gouging Laws